Copeland Capital Management LLC Trims Position in Eli Lilly and Company $LLY

Copeland Capital Management LLC trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 3.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,902 shares of the company’s stock after selling 704 shares during the period. Copeland Capital Management LLC’s holdings in Eli Lilly and Company were worth $15,949,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in LLY. Fort Washington Investment Advisors Inc. OH increased its position in shares of Eli Lilly and Company by 41.3% during the third quarter. Fort Washington Investment Advisors Inc. OH now owns 48,915 shares of the company’s stock worth $37,322,000 after acquiring an additional 14,301 shares during the period. Plimoth Trust Co. LLC grew its stake in Eli Lilly and Company by 3.9% in the third quarter. Plimoth Trust Co. LLC now owns 8,501 shares of the company’s stock worth $6,486,000 after purchasing an additional 321 shares in the last quarter. Constitution Capital LLC increased its holdings in Eli Lilly and Company by 15.0% during the 3rd quarter. Constitution Capital LLC now owns 1,530 shares of the company’s stock worth $1,167,000 after purchasing an additional 200 shares during the period. Atlas Brown Inc. raised its position in Eli Lilly and Company by 1.6% during the 3rd quarter. Atlas Brown Inc. now owns 1,969 shares of the company’s stock valued at $1,502,000 after purchasing an additional 31 shares in the last quarter. Finally, 1900 Wealth Management LLC raised its position in Eli Lilly and Company by 117.0% during the 3rd quarter. 1900 Wealth Management LLC now owns 1,098 shares of the company’s stock valued at $838,000 after purchasing an additional 592 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on LLY shares. BMO Capital Markets set a $1,200.00 price target on Eli Lilly and Company in a research report on Thursday, December 4th. CICC Research upped their price objective on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a research note on Thursday, November 13th. Weiss Ratings reissued a “buy (b-)” rating on shares of Eli Lilly and Company in a research report on Monday, December 22nd. Cantor Fitzgerald restated an “overweight” rating on shares of Eli Lilly and Company in a report on Monday, December 1st. Finally, Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Four research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,155.36.

Eli Lilly and Company Stock Performance

LLY stock opened at $1,079.84 on Wednesday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,111.99. The firm has a market cap of $1.02 trillion, a price-to-earnings ratio of 52.83, a PEG ratio of 1.09 and a beta of 0.37. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The firm has a 50-day simple moving average of $997.74 and a two-hundred day simple moving average of $845.33.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the previous year, the business posted $1.18 EPS. Eli Lilly and Company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.